Finally, in order to verify whether MAPK (Erk1/2), AKT, and NF-κB pathways are involved in enhanced GC cell proliferation and migration induced by Enah overexpression, Erk1/2, AKT and NF-κB specific inhibitors were used to treat SGC7901-LV-Enah cells and the results showed that the abilities of cell proliferation and migration were significantly downregulated in SGC7901-LV-Enah cells after treating with Erk1/2, AKT and NF-κB inhibitors. The gene discussed is MAPK3; the disease is gastric cancer.